Menu Back to The-Future-of-Drug-Device-Combination-Products-Regulation


The scope of this Workshop is Drug-Device Combination Products that are regulated as medicinal products in Europe. Here, we will have the opportunity to continue the dialogue started at the EMA sponsored workshop that took place in November 2020 and will focus on the current significant challenges brought by Article 117 of the European Medical Device Regulation (MDR), which came into effect in May 2021. This workshop will provide a neutral platform for the various stakeholders to discuss the issues and potential solutions to these challenges, with the aim of creating a consistent and predictable regulatory environment for this increasingly important category of medicines.

Featured topics

  • Challenges related to the implementation of MDR Art 117
  • Role and remit of key Stakeholders – EMA, Competent Authorities, Notified Bodies and Industry
  • How to increase clarity and predictability of regulatory expectations related to:
    • Clinical Trials
    • New Product Submissions
    • Changes and Lifecycle Management

Who should attend?

Professionals involved in:

  • CMC Regulatory Affairs
  • Device Regulatory Affairs
  • CMC Policy
  • Device Policy
  • Global Development
  • Regulatory Convergence and Reliance
  • Regulatory Compliance
  • Regulatory Policy
  • Technical Research and Development
  • CMC Lifecycle Management
  • Device Lifecycle Management
  • CMC Project Management
  • Device Project Management
  • Medical Devices and Combination Products

Learning objectives

In this Workshop we will:

  • Discuss the challenges related to the implementation of MDR Art 117, including the role and remit of the key stakeholders
  • Explore options for ensuring the effective and efficient regulatory oversight of Drug-Device Combination Products that fall within the revised legal framework introduced by Article 117 of the MDR

Program Committee

  • Amanda  Matthews
    Amanda Matthews Senior Director, GCMC for Combination Products & Medical Devices
    Pfizer R&D UK, Ltd, United Kingdom
  • Bjorg  Hunter, MSc
    Bjorg Hunter, MSc Director
    Novo Nordisk, Denmark
  • Tim  Chesworth
    Tim Chesworth Senior Director Regulatory Affairs
    AstraZeneca, United Kingdom
  • Christelle  Bouygues
    Christelle Bouygues Acting Head of Regulatory Affairs, Office Scientific and Regulatory Management
    European Medicines Agency, Netherlands
  • Ilona  Reischl, PhD, MPharm
    Ilona Reischl, PhD, MPharm Biologics Quality Assessor
    Austrian Medicines and Medical Devices Agency (AGES MEA), Austria
Load More

Contact us

Registration Questions?

Send Email
+41 61 225 51 51

Digital Learning Catalog

DIA Learning: eLearning Soultions